Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A, Glinicki P, Gietka-Czernel M.
Front Endocrinol (Lausanne). 2023 Jul 13;14:1204851. doi: 10.3389/fendo.2023.1204851. eCollection 2023.
Giant Paraganglioma Complicated With Catecholamine Crisis and Catecholamine Cardiomyopathy: A Case Report and Review of the Literature.
Ma X, Chen Z, Xia P, Zhang C, Yan K, Fan Y, Wang Y, Ti Y, Bu P.
Front Endocrinol (Lausanne). 2022 Feb 3;12:790080. doi: 10.3389/fendo.2021.790080. eCollection 2021.
Paraganglioma-induced catecholamine cardiomyopathy.
Yang Y, An Y, Bai Y, Zhang L, Li Y, Zou Y, Dai X.
Endokrynol Pol. 2025;76(2):222-223. doi: 10.5603/ep.102856.
Predictive Factors for Catecholamine-Induced Cardiomyopathy in Patients with Pheochromocytoma and Paraganglioma.
Wang Y, Yu X, Huang Y.
Front Endocrinol (Lausanne). 2022 Mar 8;13:853878. doi: 10.3389/fendo.2022.853878. eCollection 2022.
Catecholamine-induced cardiomyopathy.
Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM.
Endocr Pract. 2008 Dec;14(9):1137-49. doi: 10.4158/EP.14.9.1137.
Catecholamine-induced cardiomyopathy: an endocrinologist's perspective.
Kumar A, Pappachan JM, Fernandez CJ.
Rev Cardiovasc Med. 2021 Dec 22;22(4):1215-1228. doi: 10.31083/j.rcm2204130.
Paraganglioma presenting as acute catecholamine cardiomyopathy.
Kundu N, Traeger L, Kiu A.
ANZ J Surg. 2021 Oct;91(10):2209-2211. doi: 10.1111/ans.16661. Epub 2021 Feb 16.
Catecholamine cardiomyopathy.
Bloom S.
N Engl J Med. 1987 Oct 1;317(14):900-1. doi: 10.1056/NEJM198710013171413.
Malignant Paraganglioma With Calvarial Metastases Presenting With Recurrent Catecholamine-Induced Cardiomyopathy.
Brumley BA, Yu R, Bahri S, Rhyu J.
AACE Clin Case Rep. 2024 Sep 30;11(1):24-28. doi: 10.1016/j.aace.2024.09.006. eCollection 2025 Jan-Feb.
Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma.
Giavarini A, Chedid A, Bobrie G, Plouin PF, Hagège A, Amar L.
Heart. 2013 Oct;99(19):1438-44. doi: 10.1136/heartjnl-2013-304073. Epub 2013 Jul 9.
